MedMatrix Rx
Daily 340B Morning Briefing for Executives
Recent developments surrounding the 340B drug pricing program have sparked significant legal and financial concerns among hospitals and health systems. Hospitals have initiated a lawsuit against the Department of Health and Human Services (HHS) to block a revised rebate pilot program, which they argue could impose annual costs of up to $1 billion. Concurrently, the Centers for Medicare & Medicaid Services (CMS) has proposed cuts to 340B drug payments that could result in financial losses for health systems ranging from $7 million to $109 million each year. The Health Resources and Services Administration (HRSA) has approved ten drugmakers to participate in a pilot program that will replace upfront 340B discounts with rebates beginning in January 2027. A report has also indicated that 340B hospitals provide less charity care compared to their non-340B counterparts, raising questions about the effectiveness and benefits of the program.
EXECUTIVE SUMMARY
01
Hospitals challenge HHS’s 340B rebate pilot in court.
Hospitals have filed a lawsuit against HHS to block a revised 340B rebate program, citing potential $1 billion annual costs.
Hospitals have filed a lawsuit against HHS to block a revised 340B rebate program, citing potential $1 billion annual costs.
Source: Becker’s Hospital Review
02
CMS’s proposed 340B payment cuts could cost health systems millions.
CMS’s proposed rule to cut 340B drug payments could cost health systems between $7 million and $109 million annually.
CMS’s proposed rule to cut 340B drug payments could cost health systems between $7 million and $109 million annually.
Source: Becker’s Hospital Review
03
HRSA approves 10 drugmakers for revised 340B rebate pilot.
HRSA has approved ten drugmakers for a pilot program replacing upfront 340B discounts with rebates starting January 2027.
HRSA has approved ten drugmakers for a pilot program replacing upfront 340B discounts with rebates starting January 2027.
Source: Becker’s Hospital Review
04
340B hospitals report less charity care than non-340B hospitals.
A report shows 340B hospitals provide less charity care compared to non-340B hospitals, raising questions about program benefits.
A report shows 340B hospitals provide less charity care compared to non-340B hospitals, raising questions about program benefits.
Source: Becker’s Hospital Review
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing legal challenges and proposed payment cuts related to the 340B program present critical implications for covered entities. If the HHS rebate pilot is implemented as planned, hospitals may face substantial financial burdens that could limit their ability to provide essential services and charity care. The potential decrease in drug payment rates from CMS could exacerbate these challenges, leading to reduced operational capacity and staffing shortages. As 340B hospitals are already reporting lower levels of charity care compared to non-340B facilities, these developments could further strain their resources and impact their mission to serve vulnerable populations. The overall sustainability of the 340B program is at risk, necessitating urgent attention from stakeholders to ensure that it continues to fulfill its intended purpose.
Emerging risks.
- Hospitals face increased administrative costs if the 340B rebate model proceeds.
- Cash flow disruptions could strain hospital resources, impacting patient care.
- Legal challenges may delay the implementation of the rebate model, creating uncertainty.
- Drug manufacturers may face regulatory scrutiny over pricing practices.
- Potential changes to 340B could affect hospital financial planning and strategy.
Emerging opportunities.
- Hospitals can engage in advocacy to influence 340B program changes.
- Legal victories could reinforce hospital positions in future policy negotiations.
- Hospitals may explore alternative financial strategies to mitigate rebate model impacts.
- Engagement with policymakers could shape future 340B program reforms.
- Hospitals might seek public support to stress the importance of 340B discounts.
Key actions for providers.
- Monitor ongoing litigation for updates on the 340B rebate pilot.
- Evaluate financial strategies to manage potential rebate model impacts.
- Engage with legal counsel to understand implications of court rulings.
- Participate in advocacy efforts to influence 340B policy changes.
- Communicate with stakeholders about potential impacts of 340B program changes.
TOP STORIES
Hospitals sue HHS to block 340B rebate plan.
Becker’s Hospital Review · October 9, 2026
- AHA and others filed a lawsuit against HHS on October 9, 2026.
- The lawsuit challenges the replacement of upfront discounts with rebates.
- Hospitals claim the plan could impose over $1 billion in annual costs.
- The case was filed in the U.S. District Court for the District of Maine.
HRSA approves 10 drugmakers for 340B rebate model pilot.
Becker’s Hospital Review · October 2, 2026
- HRSA approved 10 drugmakers for a pilot replacing upfront discounts with rebates.
- The pilot includes drugs like Eliquis and Jardiance.
- It starts January 1, 2027, targeting a limited set of drugs.
- The program aims to improve claims-level transparency.
340B PROGRAM DEVELOPMENTS
340B hospitals report less charity care than non-340B hospitals.
Becker’s Hospital Review · September 28, 2026
- 340B hospitals provide less charity care than non-340B hospitals.
- Charity care differences persist for uninsured patients.
- The report uses CMS cost report data linked to HRSA records.
- The findings raise questions about the program’s benefits.
What 340B rebates could mean for hospital cash and staffing.
Becker’s Hospital Review · September 28, 2026
- The 340B rebate pilot could impact hospital cash flow.
- CEOs are concerned about potential staffing effects.
- HRSA claims the model improves claims-level transparency.
- The pilot is set to start on January 1, 2027.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D. Me. | AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Complaint for declaratory and injunctive relief. Case filed October 9, 2026. [source] | October 9, 2026 |
| Bankr. D. Del. | Akorn Holding Company LLC — Motion to Approve Compromise under Rule 9019 Filed by George L. Miller. Hearing scheduled for 11/20/2026 at 10:00 am at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom 3, Wilmington, Delaware. Case filed February 23, 2023. [source] | October 9, 2026 |
| D.D.C. | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. KENNEDY JR. — Complaint against center for medicare and medicaid innovation, centers for medicare & medicaid services, robert F. kennedy jr., mehmet oz, abe sutton, united states department of health and human services. Case filed October 7, 2026. [source] | October 7, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Amended Complaint. Case filed July 27, 2026. [source] | September 30, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Memorandum in support re Motion to Dismiss (Brief of Amicus Curiae). Case filed July 2, 2026. [source] | September 29, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| N.D. Ill. | Novartis Pharmaceuticals Corporation v. Raoul, in his official capacity as Attorney General for the State of Illinois — Order signed by the Honorable Edmond E. Chang. For the reasons stated in the Order, the motion for expedited discovery 34 is denied. Case filed August 7, 2026. [source] | September 24, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Sanofi | Credit model requiring hospitals to pay WAC and submit claims data for 340B credit. [source] | November 22, 2024 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
I searched for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.
AHA, others file suit to stop costly 340B rebate program from harming hospitals and patients
AHA News · October 9, 2026
- Main theme: AHA and partners file lawsuit against 340B rebate program
- Stakeholder sentiment: AHA President and CEO Steve Walsh: “The AHA and its member hospitals provided detailed evidence showing that the Rebate Program would impose massive new costs and divert resources that support care for millions of patients.”
- Potential implications: Potential delay or cancellation of the 340B rebate program.
- Credibility: AHA News is the official news outlet of the American Hospital Association, a reputable source.
WHAT TO WATCH NEXT
- Monitor the outcome of the AHA lawsuit against the 340B rebate pilot. [source]
- Watch for HRSA’s next steps following the approval of the 340B rebate pilot. [source]
- Follow legislative developments regarding the 340B Access Act in Congress. [source]
- Observe the impact of CMS’s new 340B data portal on compliance and reporting. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.